Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.

Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R.

Onkologie. 2010;33(10):504-11. doi: 10.1159/000319693. Epub 2010 Sep 6. Erratum in: Onkologie. 2010;33(12):725.

PMID:
20926897
2.

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.

Waller CF, Bronchud M, Mair S, Challand R.

Ann Hematol. 2010 Oct;89(10):971-8. doi: 10.1007/s00277-010-0973-6. Epub 2010 Jun 22.

3.

Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.

Park SS, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, Wong W, Kerwin BA.

J Pharm Sci. 2009 May;98(5):1688-99. doi: 10.1002/jps.21546.

PMID:
18781649
4.

Amgen swallows Micromet to BiTE into ALL market.

Sheridan C.

Nat Biotechnol. 2012 Apr 10;30(4):300-1. doi: 10.1038/nbt0412-300c. No abstract available.

PMID:
22491268
5.

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.

Waller CF, Bronchud M, Mair S, Challand R.

Ann Hematol. 2010 Sep;89(9):927-33. doi: 10.1007/s00277-010-0961-x. Epub 2010 Apr 29.

6.

Amgen spikes interest in live virus vaccines for hard-to-treat cancers.

Schmidt C.

Nat Biotechnol. 2011 Apr;29(4):295-6. doi: 10.1038/nbt0411-295. No abstract available.

PMID:
21478830
7.

Affymax poised to challenge Amgen.

Moran N.

Nat Biotechnol. 2012 May 7;30(5):377-9. doi: 10.1038/nbt0512-377. No abstract available.

PMID:
22565946
8.

Darbepoetin alfa. Amgen.

Locatelli F, Vecchio LD.

Curr Opin Investig Drugs. 2001 Aug;2(8):1097-104. Review.

PMID:
11892920
9.

A time for growth: an interview with Amgen CEO Kevin Sharer. Interview by Paul Hemp.

Sharer K.

Harv Bus Rev. 2004 Jul-Aug;82(7-8):66-74, 186.

PMID:
15241953
10.

Cinacalcet hydrochloride (Amgen).

Iqbal J, Zaidi M, Schneider AE.

IDrugs. 2003 Jun;6(6):587-92. Review.

PMID:
12811682
11.

Technology evaluation: ABX-EGF, Abgenix/Amgen.

Ranson M.

Curr Opin Mol Ther. 2003 Oct;5(5):541-6.

PMID:
14601524
12.

Technology evaluation: denosumab, Amgen.

Abrahamsen B, Teng AY.

Curr Opin Mol Ther. 2005 Dec;7(6):604-10.

PMID:
16370384
13.

Palifermin: AMJ 9701, KGF-Amgen, recombinant human keratinocyte growth factor, rHu-KGF.

[No authors listed]

Drugs R D. 2004;5(6):351-4. Review.

PMID:
15563240
14.

Deal watch: Amgen builds secondary hyperparathyroidism [corrected] pipeline.

Tse MT.

Nat Rev Drug Discov. 2012 Jun 1;11(6):430. doi: 10.1038/nrd3768. No abstract available. Erratum in: Nat Rev Drug Discov. 2012 Jul;11(7):579.

PMID:
22653204
15.

Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.

[No authors listed]

Drugs R D. 2003;4(6):349-51. Review.

PMID:
14584963
17.

PEG-sTNF-RI. Amgen.

Darlington C.

Curr Opin Investig Drugs. 2003 May;4(5):583-7. Review.

PMID:
12833653
18.

Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery.

McNiece I, Briddell R, Stoney G, Kern B, Zilm K, Recktenwald D, Miltenyi S.

J Hematother. 1997 Feb;6(1):5-11.

PMID:
9112213
19.

FDA finalizes REMS program for ESAs; Amgen continues to study risks.

Brower V.

J Natl Cancer Inst. 2010 May 5;102(9):592-3. doi: 10.1093/jnci/djq162. Epub 2010 Apr 26. No abstract available.

PMID:
20421565
20.

Deal watch: Amgen buys oncolytic virus company.

[No authors listed]

Nat Rev Drug Discov. 2011 Mar;10(3):166. doi: 10.1038/nrd3391. No abstract available.

PMID:
21358726

Supplemental Content

Support Center